Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients With Prediabetes
Status:
Completed
Trial end date:
2017-02-01
Target enrollment:
Participant gender:
Summary
Prediabetes is a term that refers to alterations in glucose homeostasis, including impaired
fasting glucose (IFG), impaired glucose tolerance (IGT) or both, involving a higher risk of
progression type 2 diabetes mellitus (T2DM).
Dapagliflozin is a selective and reversible inhibitor of sodium-glucose type 2 (SGLT-2)
co-transporter, which reduces renal glucose reabsorption and promotes the glucose excretion
through urine, so that the blood glucose is improved in patients with T2DM. Although this
mechanism is independent of insulin, there are evidence of improved secretion and insulin
sensitivity, so it is interesting to assess these effects in patients with prediabetes, as
potential therapy for treating such disorders and prevent progression to T2DM.
The aim of this study is to evaluate the effect of Dapagliflozin on insulin secretion and
insulin sensitivity in patients with prediabetes.
The investigators hypothesis is that the administration of dapagliflozin improve insulin
secretion and insulin sensitivity in patients with prediabetes.